Today’s Research Reports on Trending Tickers: Clovis Oncology and Nektar Therapeutics

NEW YORK, NY / ACCESSWIRE / April 10, 2018 / U.S. markets rallied in early trading Monday on the strength of technology stocks and the easing of trade relations between the U.S. and China. However, most of the day’s gains were lost in the final minutes of trading following news that FBI raided President Trump’s personal lawyer’s office. The Dow Jones Industrial Average gained 0.19 percent to close at 23,979.10, while the S&P 500 Index rose 0.33 percent to close at 2,613.16. The tech-heavy Nasdaq Composite Index jumped 0.51 percent to close at 6,950.34. All of the FANG (Facebook, Amazon, Netflix and Google’s parent company Alphabet) saw gains of over 1.0 percent.

“Right now, investors are learning how Trump operates in negotiating. He made an initial stance, trying to get the other side to cave in a bit, but recent commentary toward China has been more reserved and friendly, which is why we’re higher today,” said Sam Stovall, chief investment strategist of U.S. equity strategy at CFRA, according to CNBC.

RDI Initiates Coverage on:

Clovis Oncology, Inc.
https://rdinvesting.com/news/?ticker=CLVS

Nektar Therapeutics
https://rdinvesting.com/news/?ticker=NKTR

Clovis Oncology’s stock jumped 5.89% Monday, to close the day at $58.79. The stock recorded a trading volume of 2,399,106 shares, which was above its three months average volume of 1,282,236 shares. In the last year, Clovis Oncology’s shares have traded in a range of 45.42 – 99.45. The share price has gained 29.44% from its 52 week low. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $57.06 is below its 200-day moving average of $64.47. Shares of Clovis Oncology have fallen roughly 5.36 percent in the past month and are down 13.54 percent year-to-date.

Access RDI’s Clovis Oncology, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=CLVS

On Monday, shares of Nektar Therapeutics recorded a trading volume of 2,858,206 shares, which was below the three months average volume of 3,270,163 shares. The stock ended the day 11.27% higher at 104.45. The share price has gained 502.71% from its 52-week low with a 52-week trading range of 17.33 – 111.36. The company’s shares are currently trading above their 200-day moving average. The stock’s 50-day moving average of $99.41 is greater than its 200-day moving average of $61.61. Shares of Nektar Therapeutics have fallen roughly 3.59 percent in the past month and are down 74.90 percent year-to-date.

Access RDI’s Nektar Therapeutics Research Report at:
https://rdinvesting.com/news/?ticker=NKTR

Our Actionable Research on Clovis Oncology, Inc. (NASDAQ:CLVS) and Nektar Therapeutics (NASDAQ:NKTR) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute

SOURCE: RDInvesting.com

ReleaseID: 495649